Literature DB >> 16680620

Neurocognitive enhancement therapy with work therapy: Productivity outcomes at 6- and 12-month follow-ups.

Morris D Bell1, Gary J Bryson, Tamasine C Greig, Joanna M Fiszdon, Bruce E Wexler.   

Abstract

Neurocognitive enhancement therapy (NET), which involves computerized cognitive training and other methods, has been shown to improve working memory and executive function in schizophrenia. In the present study, 145 outpatients with diagnoses of schizophrenia or schizoaffective disorder recruited from a Department of Veterans Affairs mental hygiene clinic and from a community mental health center were ran domized to 6 months of paid work therapy (WT) or to NET+WT. Mixed random effects analyses revealed significant increase in hours worked and money earned over time for both conditions (p < 0.0001). NET+WT worked more hours than WT (p < 0.03), with differences emerging after rehabilitation. Responders to NET+WT worked the most during follow-up and tended to have more competitive-wage employment. Results indicate that work outcomes were enhanced by NET training. Effects were greatest for NET responders. Findings support the efficacy of cognitive training when it is integrated into broader rehabilitation programs.

Entities:  

Mesh:

Year:  2005        PMID: 16680620     DOI: 10.1682/jrrd.2005.03.0061

Source DB:  PubMed          Journal:  J Rehabil Res Dev        ISSN: 0748-7711


  36 in total

Review 1.  Cognitive enhancement as a treatment for drug addictions.

Authors:  Mehmet Sofuoglu; Elise E DeVito; Andrew J Waters; Kathleen M Carroll
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

Review 2.  Psychotherapy for schizophrenia in the year 2030: prognosis and prognostication.

Authors:  William Spaulding; Jeffrey Nolting
Journal:  Schizophr Bull       Date:  2006-08-11       Impact factor: 9.306

3.  Computer-assisted cognitive remediation in schizophrenia: what is the active ingredient?

Authors:  Matthew M Kurtz; James C Seltzer; Dana S Shagan; Warren R Thime; Bruce E Wexler
Journal:  Schizophr Res       Date:  2006-10-27       Impact factor: 4.939

4.  Neurocognition, social cognition, perceived social discomfort, and vocational outcomes in schizophrenia.

Authors:  Morris Bell; Hector W H Tsang; Tamasine C Greig; Gary J Bryson
Journal:  Schizophr Bull       Date:  2008-01-31       Impact factor: 9.306

5.  A randomized controlled trial of cognitive remediation and work therapy in the early phase of substance use disorder recovery for older veterans: Neurocognitive and substance use outcomes.

Authors:  Morris D Bell; Holly B Laws; Ismene B Petrakis
Journal:  Psychiatr Rehabil J       Date:  2016-10-10

6.  Compensatory cognitive training for people with severe mental illnesses in supported employment: A randomized controlled trial.

Authors:  Elizabeth W Twamley; Kelsey R Thomas; Cynthia Z Burton; Lea Vella; Dilip V Jeste; Robert K Heaton; Susan R McGurk
Journal:  Schizophr Res       Date:  2017-08-18       Impact factor: 4.939

7.  Developing a Cognitive Training Strategy for First-Episode Schizophrenia: Integrating Bottom-Up and Top-Down Approaches.

Authors:  Keith H Nuechterlein; Joseph Ventura; Kenneth L Subotnik; Jacqueline N Hayata; Alice Medalia; Morris D Bell
Journal:  Am J Psychiatr Rehabil       Date:  2014-07

8.  A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians.

Authors:  Irene M Hurford; Stephen R Marder; Richard S E Keefe; Steven P Reise; Robert M Bilder
Journal:  Schizophr Bull       Date:  2009-09-23       Impact factor: 9.306

9.  Multimodal cognitive therapy: combining treatments that bypass cognitive deficits and deal with reasoning and appraisal biases.

Authors:  Dawn I Velligan; Meredith Draper; Donna Stutes; Natalie Maples; Jim Mintz; Sara Tai; Douglas Turkington
Journal:  Schizophr Bull       Date:  2009-07-20       Impact factor: 9.306

10.  Intrinsic motivation and learning in a schizophrenia spectrum sample.

Authors:  Jimmy Choi; Alice Medalia
Journal:  Schizophr Res       Date:  2009-08-27       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.